Sign In
Buy RVMD
$155.99
+4.68 (+3.09%)
At Close: Jun 03, 2026
Underwriters' full exercise of option brings gross proceeds to $862.5 million Underwriters' full exercise of option brings gross proceeds to $862.5 million
Revolution Medicines: Risky Buy On Recent Share Price Dip
09:09am, Wednesday, 04'th Dec 2024
Revolution Medicines' stock has surged over 30% since April, driven by promising clinical data for its lead asset, RMC-6236, targeting RAS-mutated cancers. RMC-6236 shows best-in-class efficacy in PDA
Revolution Medicines Announces Pricing of Upsized $750.0 Million Public Offering of Common Stock and Pre-Funded Warrants
10:38pm, Tuesday, 03'rd Dec 2024
REDWOOD CITY, Calif., Dec. 03, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted cancer
Revolution Medicines Announces Commencement of Public Offering of Common Stock
04:31pm, Monday, 02'nd Dec 2024
REDWOOD CITY, Calif., Dec. 02, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted cancer
Revolution Medicines Provides Clinical Updates from its RAS(ON) Inhibitor Portfolio
07:30am, Monday, 02'nd Dec 2024
Compelling Phase 1/1b update on RMC-6236 monotherapy in second-line metastatic pancreatic ductal adenocarcinoma supports ongoing Phase 3 RASolute 302 clinical trial
Revolution Medicines to Host RAS(ON) Inhibitor Clinical Update Webcast on December 2, 2024
04:05pm, Wednesday, 27'th Nov 2024
REDWOOD CITY, Calif., Nov. 27, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted cancer
Revolution Medicines, Inc. (RVMD) Q3 2024 Earnings Call Transcript
07:52pm, Wednesday, 06'th Nov 2024
Revolution Medicines, Inc. (RVMD) Q3 2024 Earnings Call Transcript
Revolution Medicines Reports Third Quarter 2024 Financial Results and Update on Corporate Progress
04:02pm, Wednesday, 06'th Nov 2024
Phase 3 pivotal trial underway evaluating RMC-6236 in patients with metastatic pancreatic ductal adenocarcinoma (PDAC), supported by compelling clinical profile
Revolution Medicines to Participate in Upcoming Investor Conferences
09:00am, Tuesday, 05'th Nov 2024
REDWOOD CITY, Calif., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today annou
Revolution Medicines to Report Financial Results for Third Quarter 2024 After Market Close on November 6, 2024
04:05pm, Wednesday, 30'th Oct 2024
REDWOOD CITY, Calif., Oct. 30, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted cancer
First clinical results for RMC-9805, a RAS(ON) G12D-selective inhibitor, demonstrate encouraging tolerability and antitumor activity in patients with PDAC
Revolution Medicines Presents Updated Data from RMC-6236 Monotherapy Study in Patients with Advanced Pancreatic Ductal Adenocarcinoma
06:00am, Wednesday, 23'rd Oct 2024
Encouraging progression-free survival and overall survival profile Safety findings consistent with previously reported data, no new safety signals observed Investor webcast to be held Friday, October
REDWOOD CITY, Calif., Oct. 21, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted cancer
Revolution Medicines to Deliver Multiple Presentations at the 2024 AACR-NCI-EORTC Symposium and Host Investor Webcast
09:00am, Monday, 07'th Oct 2024
Pancreatic ductal adenocarcinoma (PDAC) data from RMC-6236 (RAS(ON) multi-selective inhibitor) and RMC-9805 (RAS (ON) G12D-selective inhibitor) monotherapy studies to be featured in two late-breaking
Revolution Medicines, Inc. (RVMD) Q2 2024 Earnings Call Transcript
02:00am, Sunday, 11'th Aug 2024
Revolution Medicines, Inc. (NASDAQ:RVMD ) Q2 2024 Earnings Conference Call August 7, 2024 4:30 PM ET Company Participants Ryan Asay - Senior Vice President of Corporate Affairs Mark Goldsmith - Chairm
